Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORLESTRIN FE 2.5/50 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation by suppressing gonadotropin-releasing hormone (Gn RH) via negative feedback on the hypothalamus and pituitary. Increases cervical mucus viscosity to impede sperm penetration and induces endometrial atrophy to prevent implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy (FDA-approved),Treatment of moderate acne vulgaris (in women ≥15 years who desire oral contraception, have no contraindications, and have not achieved success with topical agents),Management of menstrual disorders (off-label)
Prevention of pregnancy
One tablet orally once daily, each containing 2.5 mg norethindrone acetate and 50 mcg ethinyl estradiol, plus 7 iron tablets (75 mg ferrous fumarate) taken during the placebo week.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: ~8-10 hours (terminal), requiring daily dosing for stable contraceptive effect. Ethinyl estradiol: ~13-21 hours (terminal), supporting once-daily administration.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Hepatic metabolism via cytochrome P450 (CYP) enzymes: ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone undergoes reduction, hydroxylation, and conjugation. Both undergo enterohepatic recirculation and are excreted in urine and feces.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal, with enterohepatic recirculation.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: ~61-70% bound to albumin and SHBG. Ethinyl estradiol: ~97-98% bound to albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: Vd ~1.8-4.5 L/kg (extensive tissue distribution). Ethinyl estradiol: Vd ~2.5-5 L/kg (distributes into breast milk).
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Norethindrone: ~64% (oral). Ethinyl estradiol: ~38-48% (oral) due to first-pass metabolism.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No specific dose adjustment provided; contraindicated in severe renal impairment (GFR <30 m L/min) due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in severe hepatic disease (Child-Pugh class C); use with caution in mild to moderate impairment (Child-Pugh A or B) with monitoring for adverse effects; no specific dose reduction guidelines established.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche; post-menarche: same as adult dosing (one tablet daily) after menstrual cycle establishment.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for postmenopausal women; no dose adjustment in elderly with normal hepatic and renal function, but consider increased risk of thromboembolic events and metabolic effects.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism) from combination oral contraceptive use. Risk increases with age and number of cigarettes smoked. Women over 35 years who smoke should not use this combination oral contraceptive.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thromboembolic disorders: increased risk of venous thromboembolism (VTE) and arterial thrombosis; discontinue if suspected,Cardiovascular disease: increased risk of myocardial infarction and stroke, especially in smokers >35 years,Hypertension: may develop or worsen; monitor blood pressure,Cervical cancer: controversial association; Pap smear screening recommended,Hepatic neoplasia: rare but reported; contraindicated with active liver disease,Gallbladder disease: increased risk of cholelithiasis,Ocular effects: retinal thrombosis may occur; discontinue if sudden partial or complete vision loss,Carbohydrate metabolism: may decrease glucose tolerance; monitor diabetic patients,Fluid retention: use with caution in conditions affected by edema (e.g., migraine, asthma, renal impairment)
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma, endometrial carcinoma, or estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Benign or malignant liver tumor (current or history),Active liver disease (e.g., acute viral hepatitis) or impaired liver function,Hypersensitivity to any component of the product,Cigarette smoking in women over 35 years of age
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice as they may increase estrogen levels and side effects. No specific food restrictions otherwise. Iron from ferrous fumarate may be affected by calcium-rich foods or supplements; take iron at least 2 hours apart from dairy products.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
NORLESTRIN FE 2.5/50 (norethindrone acetate 2.5 mg/ethinyl estradiol 0.05 mg) is contraindicated in pregnancy. First trimester: increased risk of congenital anomalies including cardiovascular and limb defects, and possible non-genital malformations. Second/third trimester: feminization of male fetus, vaginal adenosis, and cervical changes in females. Exposure is associated with a 1.3 to 2.0-fold increased risk of congenital heart defects.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Norethindrone and ethinyl estradiol are excreted into breast milk. M/P ratio for norethindrone is approximately 1.1; for ethinyl estradiol approximately 0.3. Use during lactation may reduce milk production and quality. Not recommended for nursing mothers.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dosing adjustments are applicable as drug is contraindicated in pregnancy. Higher baseline estradiol levels in pregnancy do not necessitate dose changes because use is not recommended.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
NORLESTRIN FE 2.5/50 contains norethindrone 2.5 mg and ethinyl estradiol 50 mcg, plus ferrous fumarate (75 mg) as a placebo. The high estrogen dose (50 mcg) increases thromboembolic risk; avoid in patients with migraine with aura, hypertension, or smoking >35 years. Iron supplementation can cause dark stools. The formulation includes 7 iron-containing placebo tablets to maintain cycle control and prevent iron deficiency.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time, preferably after an evening meal to reduce nausea.,Missed dose: If one day, take as soon as remembered; if two days, take two tablets then resume schedule; if more, use backup contraception and consult healthcare provider.,Report signs of blood clots: chest pain, sudden shortness of breath, leg pain/swelling, or severe headache.,Iron supplements may cause dark stools; this is harmless.,Do not smoke while taking this medication as it increases risk of serious cardiovascular side effects.,Antibiotics (e.g., rifampin), anticonvulsants, and St. John's Wort may decrease effectiveness; use alternative contraception.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORLESTRIN FE 2.5/50 vs ALYACEN 1/35, answered by our medical review team.
NORLESTRIN FE 2.5/50 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation by suppressing gonadotropin-releasing hormone (Gn RH) via negative feedback on the hypothalamus and pituitary. Increases cervical mucus viscosity to impede sperm penetration and induces endometrial atrophy to prevent implantation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORLESTRIN FE 2.5/50 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORLESTRIN FE 2.5/50 is: One tablet orally once daily, each containing 2.5 mg norethindrone acetate and 50 mcg ethinyl estradiol, plus 7 iron tablets (75 mg ferrous fumarate) taken during the placebo week.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORLESTRIN FE 2.5/50 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORLESTRIN FE 2.5/50 is classified as Category C. NORLESTRIN FE 2.5/50 (norethindrone acetate 2.5 mg/ethinyl estradiol 0.05 mg) is contraindicated in pregnancy. First trimester: increased risk of congenital anomalies including car. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.